Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Rhea-AI Summary

Tevogen Bio (NASDAQ:TVGN) has reaffirmed its strong market position with an estimated asset value exceeding $10 billion, according to investor HMP Partners and The Patel Family LLP. This valuation represents significant growth from its $4.2 billion valuation in 2022 when it was recognized as the highest-valued biotech unicorn.

The increased valuation is attributed to several key achievements, including granted patents, a diverse product pipeline across multiple therapeutic areas, and a successful proof-of-concept clinical trial. CEO Dr. Ryan Saadi announced plans to share details of their proprietary valuation model with investors, highlighting the company's platform technologies, AI initiatives, and pipeline potential.

Positive

• Asset value increased from $4.2 billion in 2022 to over $10 billion in 2025
• Successfully completed positive proof-of-concept clinical trial
• Secured multiple granted patents across various therapeutic areas
• Developed robust intellectual property and product portfolio with significant revenue potential

Negative

• Current valuation is based on internal estimates and investor assessment, not independent third-party validation
• Details of the proprietary valuation model are not yet disclosed

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion.

In October 2024, HMP Partners and The Patel Family LLP, investors in innovative healthcare ventures, congratulated Tevogen Bio and Dr. Ryan Saadi for their efforts to alleviate health inequality through breakthrough life-saving medical innovations. Hema Patel, Managing Partner of HMP Partners and The Patel Family LLP, remarked, “We are impressed by Leadership's extensive industry experience resulting in achieving key milestones in record times including granted patents and a product pipeline in multiple therapeutic areas. In 2022, Tevogen Bio was named as the highest-valued biotech unicorn at $4.2 billion.” Speaking to the Company’s internal assets valuation, Hema added, “With further advancements, including positive proof-of-concept clinical trial, we estimate current market value of its robust intellectual property and product portfolio excluding other assets to exceed $10 billion in current market value with significant revenue potential.”

Dr. Ryan Saadi, Founder and CEO of Tevogen, stated, “Our internal proprietary valuation model underscores the tremendous potential of Tevogen’s platform technologies, artificial intelligence initiative, and pipeline. We look forward to sharing details from this model with the investment community in the coming days, further demonstrating the strength of our intellectual property and the scale of our commercial opportunities.”

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What is Tevogen Bio's (TVGN) current estimated asset value in 2025?

According to investor estimates, Tevogen Bio's current market value of its intellectual property and product portfolio exceeds $10 billion, excluding other assets.

How much has Tevogen Bio's valuation increased since 2022?

Tevogen Bio's valuation has increased from $4.2 billion in 2022, when it was the highest-valued biotech unicorn, to over $10 billion in 2025.

What factors contributed to Tevogen Bio's (TVGN) increased valuation?

The increased valuation is attributed to granted patents, product pipeline development across multiple therapeutic areas, positive proof-of-concept clinical trial results, and advancements in platform technologies and AI initiatives.

Who are the key investors supporting Tevogen Bio's valuation?

HMP Partners and The Patel Family LLP, led by Managing Partner Hema Patel, are the key investors who provided the current valuation estimate.

When will Tevogen Bio release details of its valuation model?

According to CEO Dr. Ryan Saadi, the company plans to share details of its proprietary valuation model with the investment community in the coming days.